AnBogen Therapeutics
Latest round
- Series A
Last raised
- Feb 2024
Total raised
- $13M
Investors
- 4
About AnBogen Therapeutics
Established in 2019 and based in Taipei, China, AnBogen Therapeutics, Inc. operates as a drug development company that develops oncology drugs. The company was founded by its CEO, Tsu-An Hsu, Chuan Shih, and Hsing-Pang Hsieh. AnBogen Therapeutics, Inc. offers a clinical-stage biotechnology platform, which is a cancer drug development platform that develops medicines, mainly precision oncology drugs, for cancer patients. The company develops drugs with the help of its drug candidates: ABT-101, an oral tyrosine kinase inhibitor (TKI) for non-small cell lung cancer; ABT-202, a second-generation KRAS inhibitor; and ABT-301, a small-molecule histone deacetylase inhibitor (HDACi) for treating various solid tumors. The company’s revenue is generated by providing oncology treatment drugs.
Who invested in AnBogen Therapeutics
4 investors across 1 round
See all investors in AnBogen Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 1, 2024
Amount
$13M
Investors
Questions about AnBogen Therapeutics
Who invested in AnBogen Therapeutics?
AnBogen Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AnBogen Therapeutics raised?
AnBogen Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AnBogen Therapeutics last raise money?
AnBogen Therapeutics's most recent round on record is a Series A, in Feb 2024.
What does AnBogen Therapeutics do?
Established in 2019 and based in Taipei, China, AnBogen Therapeutics, Inc.
Where is AnBogen Therapeutics headquartered?
AnBogen Therapeutics is headquartered in Taipei, Taiwan - China.
Which VCs invest in companies like AnBogen Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AnBogen Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like AnBogen Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.